Qurient, a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organisation dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs, have entered into a license agreement to develop and commercialise telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis (TB) and other non-tuberculosis mycobacterium infections.